Stephens Begins Coverage on Definitive Healthcare (NASDAQ:DH)

Stock analysts at Stephens began coverage on shares of Definitive Healthcare (NASDAQ:DH) in a research note issued to investors on Friday, Marketbeat.com reports. The brokerage set an “equal weight” rating and a $5.00 price target on the stock. Stephens’ price objective would suggest a potential upside of 19.62% from the company’s current price.

Other analysts have also recently issued research reports about the stock. BTIG Research assumed coverage on shares of Definitive Healthcare in a research note on Tuesday, September 17th. They set a “buy” rating and a $7.00 price target for the company. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $5.72.

Definitive Healthcare Trading Up 1.0 %

DH opened at $4.18 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. Definitive Healthcare has a one year low of $3.19 and a one year high of $10.62. The company has a market cap of $482.89 million, a P/E ratio of -1.35, a PEG ratio of 3.29 and a beta of 1.40. The business’s 50-day simple moving average is $4.41 and its 200-day simple moving average is $4.68.

Insider Transactions at Definitive Healthcare

In related news, insider William Moschella sold 45,000 shares of the stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the transaction, the insider now directly owns 433,830 shares of the company’s stock, valued at approximately $2,039,001. This trade represents a 9.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 14.84% of the company’s stock.

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds have recently modified their holdings of DH. 272 Capital LP lifted its stake in shares of Definitive Healthcare by 74.8% in the third quarter. 272 Capital LP now owns 1,114,080 shares of the company’s stock worth $4,980,000 after acquiring an additional 476,766 shares in the last quarter. Barclays PLC increased its holdings in Definitive Healthcare by 318.8% during the 3rd quarter. Barclays PLC now owns 81,916 shares of the company’s stock worth $366,000 after purchasing an additional 62,354 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Definitive Healthcare in the 3rd quarter valued at approximately $93,000. State Street Corp boosted its stake in shares of Definitive Healthcare by 29.4% during the 3rd quarter. State Street Corp now owns 1,399,729 shares of the company’s stock valued at $6,257,000 after buying an additional 317,952 shares during the last quarter. Finally, Point72 DIFC Ltd grew its position in shares of Definitive Healthcare by 759.9% during the third quarter. Point72 DIFC Ltd now owns 9,296 shares of the company’s stock worth $42,000 after buying an additional 8,215 shares in the last quarter. 98.67% of the stock is currently owned by hedge funds and other institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.